Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis

Table of Contents

1. COPD Industry: An Overview

2. Worldwide COPD Market

• 2.1 COPD Medication
  • 2.1.1 Spiriva
  • 2.1.2 Advair
  • 2.1.3 Symbicort/ Pulmicort
  • 2.1.4 Brovana
  • 2.1.5 Xopenex

3. Prevalence and Mortality Rate of COPD

• 3.1 Prevalence in United States
• 3.2 Prevalence in Australia
• 3.3 Mortality Rate of COPD

4. Economic Cost

• 4.1 United States
• 4.2 Australia

5. Industry Analysis

• 5.1 Future Trends
  • 5.1.1 Respiratory Medications Market
  • 5.1.2 Prevalence Rate Continues to Grow

6. Growth Drivers

• 6.1 Indoor Air Pollutants
• 6.2 Occupational Exposure
• 6.3 Aging Population Leads to Surge in COPD
• 6.4 Smoking - A Leading cause of COPD
• 6.5 Air Pollution

7. Company Profiles

• 7.1 Glaxo Smith Kline
  • 7.1.1 Overview
  • 7.1.2 Business Strategies
  • 7.1.3 Business and Product Expansion
  • 7.1.4 Diversify Through Externalization
  • 7.1.5 Re-Shape Manufacturing
• 7.2 AstraZeneca plc
  • 7.2.1 Overview
  • 7.2.2 Business Strategies
  • 7.2.3 Diversified Areas of Research
  • 7.2.4 Strong Presence in Emerging Markets
• 7.3 Merck & Co.
  • 7.3.1 Overview
  • 7.3.2 Business Strategies
  • 7.3.3 Rolling Out a Customer-Centric Selling Model

8. Market Outlook

• 8.1 Market Forecast
• 8.2 Forecast Methodology
  • 8.2.1 Dependent and Independent Variables
  • 8.2.2 Correlation Analysis
  • 8.2.3 Regression Analysis

List of Tables

• COPD Prevalence Rates by Age and Gender in Australia (2007)
• Relative Risk of Mortality Due to COPD
• Comparison of Costs Associated with COPD in Various Countries
• COPD Cost by Type of Cost and Bearer in Australia (2008)
• Value of Independent Variable (2002-08)
• Correlation Table
• Model Summary - Coefficient of Determination
• Regression Table - Summary of Coefficients

List of Charts

• Total Respiratory Disease Market Comparison (2001-06)
• Worldwide COPD Market by Value (2003-12E)
• Spiriva Market Value and Forecast (2002-11E)
• Advair Sales and Forecast (2007-13E)
• Flixotide Sales and Forecast (2007-13E)
• Symbicort/Pulmicort Revenue and Forecast (2007-13E)
• Singulair Revenue and Forecast (2007-13E)
• Market Share of HFA-Based Short Acting Beta Agonists (2006-07)
• Chronic Bronchitis - Percentage Distribution by Gender (2007)
• Prevalence by Geographic Region (2007)
• Emphysema, Percentage Distribution by Gender (2007)
• Prevalence of COPD in Australia (2008)
• Economic Cost of Selected Lung Diseases in US (2007)
• Distribution of COPD Cost (2007)
• Financial Cost of COPD by Type of Cost (2007)
• Expected Respiratory Market Size and COPD Share (2010-16E)
• COPD by Severity, Projected Prevalence (2008-50E)
• Worldwide Aging Population (2000-10E)
• Worldwide Number of Smokers (2000-10E)
• Worldwide Carbon Dioxide Emissions (2004-30E)
• GSK Revenues (2006-08)
• AstraZeneca Revenues by Geography (2006-08)
• Merck Revenues by Business Segments (2006-08)
• Worldwide COPD Market Forecast (2009-10E)